FDA pharmacologic class
Janus Kinase Inhibitor
7 medicines are in FDA's class of janus kinase inhibitors: tofacitinib (Xeljanz), ruxolitinib (Opzelura), abrocitinib (Cibinqo), baricitinib (Olumiant), upadacitinib (Rinvoq), delgocitinib (Anzupgo) and deuruxolitinib (Leqselvi). 1 of the 7 are listed from generic labelers (FDA NDC Directory, October 8, 2026). The lowest pharmacy cost is tofacitinib 5 mg tablet at $0.573 per tablet (NADAC).
Which medicines are janus kinase inhibitor?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Tofacitinib | Xeljanz | 24 labelers | $0.573 per tablet 5 mg tablet | Yes | No current entry | 0 |
| Ruxolitinib | Jakafi, Opzelura | none listed | $34.01 per gram 1.5% cream | No | No current entry | 0 |
| Abrocitinib | Cibinqo | none listed | $197.09 per tablet 100 mg tablet | Yes | No current entry | 0 |
| Baricitinib | Olumiant | none listed | $92.54 per tablet 2 mg tablet | Yes | No current entry | 0 |
| Upadacitinib | Rinvoq | none listed | $229.31 per tablet 15 mg tablet | Yes | No current entry | 0 |
| Delgocitinib | Anzupgo | none listed | n/a | No | No current entry | 0 |
| Deuruxolitinib | Leqselvi | none listed | n/a | Yes | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price